Eight Causes of Insulin Resistance in Type 1 Diabetes

1. Beta-cell dysfunction — residual insulin and C-peptide effects

What it is: in type 1 diabetes, beta-cell insulin production is severely reduced. However, some people retain measurable C-peptide (and therefore some endogenous insulin) for years, especially when diagnosed later in life.

Why it matters in T1D: even tiny amounts of endogenous insulin can have outsized benefits because it is delivered into the portal circulation and pancreatic microenvironment — which injected insulin cannot replicate.

• Some insulin may still be produced, even if only in tiny amounts.
• Endogenous insulin helps suppress glucagon output from alpha cells (a local paracrine effect).
• Glucotoxicity (high glucose) can impair remaining beta-cell function further.

How it tends to show up: people with residual function often need less insulin and experience less volatility. As insulin resistance rises, the buffering effect of residual beta-cell function weakens, and glucagon regulation tends to worsen.

2. Muscle insulin resistance — reduced glucose uptake

What it is: skeletal muscle is the largest site of insulin-stimulated glucose disposal. When muscle becomes insulin resistant, glucose stays in the bloodstream and more insulin is required to push glucose into muscle after meals and during corrections.

Mechanism: one major driver is lipid accumulation inside muscle cells. When diacylglycerols (DAG) and ceramides build up, they disrupt insulin signalling and reduce GLUT4 translocation — meaning glucose uptake slows even when insulin is present.

This is one reason high-fat meals can produce delayed glucose rises hours later. The DAG mechanism diagram in the high-fat meals guide illustrates this pathway.

Why it matters in T1D: injected insulin creates relatively high peripheral insulin exposure (muscle and fat), which can promote fat storage and gradually worsen muscle insulin signalling — especially when activity is low.

How it tends to show up:

• Higher meal insulin requirements over time.
• Corrections that work poorly unless activity increases.
• Delayed post-meal hyperglycaemia after high-fat meals.

3. Liver insulin resistance — glucose output that persists

What it is: the liver produces glucose during fasting (glycogenolysis and gluconeogenesis). Insulin normally suppresses this output rapidly. When the liver becomes insulin resistant, glucose output continues even when insulin levels appear sufficient.

Why it matters in T1D: the liver normally receives insulin first via the portal vein. In T1D, insulin is delivered subcutaneously, and portal insulin levels are often lower than physiological. This creates a mismatch: the liver can be under-insulinised even when peripheral tissues are over-insulinised.

How it tends to show up:

• Dawn phenomenon and overnight glucose drift upwards.
• High fasting glucose despite reasonable basal dosing.
• Glucose rising even without food.

Amplifier: glucagon excess (common in T1D) further drives hepatic glucose output — and liver insulin resistance makes glucagon’s effect stronger.

4. Fat-cell dysfunction — excess free fatty acid flux

What it is: fat tissue stores fatty acids and releases them when needed. Insulin normally suppresses fat release (anti-lipolysis). In insulin resistance, fat tissue becomes less responsive to insulin, and free fatty acids (FFAs) leak into circulation more continuously.

Why it matters in T1D: elevated FFAs directly worsen insulin resistance in liver and muscle (via lipid signalling and mitochondrial overload), increasing insulin requirements and amplifying glucose variability.

What tends to happen:

• FFAs interfere with insulin signalling in muscle and liver.
• FFAs increase hepatic glucose output.
• Glucose becomes harder to stabilise without increasing insulin doses.

How it tends to show up: rising total daily insulin alongside fat gain (especially visceral fat), more variability, and a more resistant pattern to meals and corrections.

5. Kidney dysfunction — glucose reabsorption as a set point

What it is: the kidneys filter glucose continuously and reabsorb most of it via SGLT2 transporters. If blood glucose rises high enough, glucose spills into urine.

Important: the renal threshold is not a fixed value — it varies between individuals and can change over time — so it is worth avoiding the assumption that 10.0 mmol/L is a universal cutoff.

Why it matters: in insulin resistant states, evidence suggests the kidney can reabsorb more glucose (a higher threshold), meaning hyperglycaemia persists longer and insulin has to do more work to bring glucose down.

How it tends to show up: sustained highs that are harder to break once glucose is elevated, and more momentum towards prolonged hyperglycaemia.

6. Brain insulin resistance — appetite and defensive physiology

What it is: insulin acts in the brain (especially the hypothalamus) as a signal of energy abundance. It contributes to satiety and helps regulate appetite, reward, and autonomic output.

In insulin resistance, the brain becomes less responsive to insulin signalling, which promotes hunger and undermines weight regulation. In T1D there is an additional layer: recurrent hypoglycaemia (or fear of it) can bias behaviour and physiology towards defensive eating and higher glucose targets.

How it tends to show up:

• Increased hunger and cravings.
• Difficulty losing weight without destabilising glucose.
• More frequent eating to prevent or treat lows.

7. Gut hormone dysfunction — GLP-1, GIP, and gastric emptying

What it is: after eating, K and L cells release incretin hormones (notably GLP-1 and GIP). These influence glucose control through multiple pathways:

• Stimulate insulin secretion from any remaining beta cells.
• Suppress glucagon secretion.
• Signal satiety in the brain.
• Slow gastric emptying (delaying glucose absorption).

Why it matters in T1D: even without beta-cell insulin secretion, GLP-1 effects still matter via appetite regulation, gastric emptying, and glucagon suppression — which is why GLP-1 receptor agonists can meaningfully reduce insulin requirements in some people with T1D.

How it tends to show up: reduced satiety signalling, sharper post-meal excursions (faster gastric emptying), and higher insulin needs via increased intake and altered meal kinetics.

8. Alpha-cell dysfunction — the insulin opponent that persists

What it is: glucagon is insulin’s functional opposite. It tells the liver to release glucose. In people without diabetes, glucagon falls after meals and rises during hypoglycaemia.

In T1D, alpha cells often become dysregulated: glucagon may be too high when glucose is high, and too low when glucose is low. This increases glucose volatility and drives higher insulin requirements.

Why it matters in T1D: injected insulin does not provide the same pancreatic micro-signal that endogenous insulin provides to suppress glucagon. Residual beta-cell function helps here — but many people have none.

How it tends to show up:

• Overnight hepatic glucose output and fasting highs.
• Exaggerated post-meal spikes (especially protein-driven excursions).
• Higher basal requirements and more stubborn correction resistance.